Resverlogix Corp. (TSE:RVX – Get Free Report) hit a new 52-week low on Thursday. The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 3,151 shares changing hands. The stock had previously closed at C$0.09.
Resverlogix Stock Performance
The company has a debt-to-equity ratio of -82.47, a quick ratio of 0.04 and a current ratio of 0.04. The company has a 50 day moving average price of C$0.09 and a 200 day moving average price of C$0.10. The company has a market capitalization of C$29.26 million, a price-to-earnings ratio of -2.12 and a beta of -0.11.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Read More
- Five stocks we like better than Resverlogix
- MarketBeat Week in Review – 10/05 – 10/09
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
